FIELD: medicine.
SUBSTANCE: invention describes a method for prediction of progression of cystic fibrosis diagnosed by neonatal screening taking into account sex, age; values of haemoglobin, leukocytes, alanine transaminase, aspartate transaminase, C-reactive protein; type of bacterial flora in nasal and pharyngeal smears, sweat chloride test to determine a prognostic coefficient of progression of cystic fibrosis (Kpcf) with using a regression equation: Kpcf=3.21946+0.526873*sex - 0.0488185*age - 0.0125638*haemoglobin+0.0302588*leukocytes - 0.0418016*alanine transaminase+0.00832224*aspartate transaminase+0,0736644*CRP+; 0.238719* nasal flora+0.442044* pharyngeal flora - 0.00669528*sweat chlorides, wherein: sex - 1 for boys, 0 for girls; age - completed months at the moment of examination; haemoglobin is peripheral blood haemoglobin, gram per litre, leukocytes is leukocyte count in cubic millimetre of peripheral blood; alanine transaminase is venous blood alanine transaminase, units per litre; aspartate transaminase is venous blood aspartate transaminase, units per litre; CRP is C-reactive protein, milligram per litre; nasal flora and pharyngeal flora is a type of bacterial flora in nasal smears and pharyngeal smears: 1 streptococcus, 2 Pseudomonas Aureginosa; 3 staphylococcus; 4 fungi; 5 no flora growth found (a smear is sterile); 6 enterococcus; 7 corynebacteria; 8 Neisseria; 9 acinetobacteria; 10 Escherichia coli; 11 Citrobacter; 12 Klebsiella; 13 Stenotrophomonas; 14 Haemophilus influenzae; 15 moraxella; 16 other types of flora; sweat chlorides is sweat chlorides, mmole/l; if the coefficient is less than 2.3, the course of the disease is predicted to be positive; if the coefficient is 2.3 and more, cystic fibrosis is predicted to aggravate.
EFFECT: method enables reducing time consumption, requires no highly experienced doctors to be involved; it has the high accuracy and specificity.
1 tbl, 2 ex
Title | Year | Author | Number |
---|---|---|---|
COMPLEX THERAPY METHOD FOR TREATING CHILDREN FOR SEVERE MUCOVISCIDOSIS | 2005 |
|
RU2318522C2 |
METHOD FOR PATHOGENETIC CORRECTION OF METABOLIC DISORDERS IN INFECTIOUS MONONUCLEOSIS CAUSED BY EPSTEIN-BARR VIRUS | 2020 |
|
RU2726070C1 |
METHOD OF TREATING OXALATE NEPHROPATHY IN CHILDREN | 2020 |
|
RU2738552C1 |
METHOD FOR ABORTION THREAT PREDICTION IN THE SECOND TRIMESTER FOR WOMEN WITH CHORION LOCATION ANOMALIES | 2015 |
|
RU2618403C1 |
METHOD OF TREATING PATIENTS WITH INTESTINAL DYSBACTERIOSIS | 2009 |
|
RU2400235C1 |
METHOD FOR EARLY DIAGNOSTICS OF NEONATAL SEPSIS | 2021 |
|
RU2755218C1 |
METHOD OF TREATING PATIENTS WITH CHRONIC LIVER DISEASES IN STAGE OF LATENCY AND DEGREE I MANIFESTED STAGE OF HEPATIC ENCEPHALOPATHY | 2011 |
|
RU2462251C1 |
METHOD OF PERSONIFIED PREDICTION OF CLINICAL EFFECTIVENESS OF NON-ALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH METABOLIC SYNDROME | 2020 |
|
RU2737503C1 |
METHOD OF PREDICTING THE RISK OF DEVELOPING CHRONIC HEART FAILURE IN PATIENTS WHO HAVE HAD A NEW CORONAVIRUS INFECTION COVID-19 | 2023 |
|
RU2805601C1 |
METHOD OF EARLY PROGNOSIS OF THE NATURE OF THE COURSE OF ACUTE RESPIRATORY INFECTION IN CHILDREN | 2017 |
|
RU2659384C1 |
Authors
Dates
2014-07-27—Published
2013-01-31—Filed